Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI model aims to predict ICU deaths from superbug blood infections

NCT ID NCT06167083

Knowledge-focused Sponsor: Kocaeli University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 197 ICU patients with bloodstream infections caused by carbapenem-resistant bacteria (superbugs). Researchers used machine learning to analyze patient data and predict which patients were at higher risk of dying. The goal is to create a tool that helps doctors act faster for the sickest patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a tool that helps doctors identify high-risk patients earlier, potentially improving care in the ICU.
What could go wrong
This is a small, retrospective study from a single hospital, so the model may not work well in other settings. It is not a treatment and does not directly help patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

197 people

The number who actually took part.

Started

Apr 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients who were monitored in our tertiary intensive care unit for six years retrospectively and developed bloodstream infections with Carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa have been included in the study with their personal data anonymized

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * In our study, patients who were monitored in our hospital's tertiary Intensive Care Unit between June 2017 and June 2023 and developed bloodstream infections with Carbapenem-resistant Enterobacteriaceae, Carbapenem-resistant Acinetobacter baumannii and Carbapenem-resistant Pseudomonas aeruginosa will be retrospectively included. Exclusion Criteria: * Patients under the age of 18 and those with infections other than bloodstream infections will not be included.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carbapenem resistant bacterial infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acinetobacter infectious disease Pseudomonas aeruginosa infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carbapenem resistant bacterial infection

Contacts and locations

Locations

  • Kocaeli University

    Kocaeli, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.